Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

COMPASS Pathways Plc - American Depository Shares (NQ: CMPS )

7.860 -0.060 (-0.76%)
Streaming Delayed Price Updated: 3:47 PM EDT, May 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about COMPASS Pathways Plc - American Depository Shares

< Previous 1 2
...
18 19 20 21 22 23 24 25 Next >
Psyched: British PM Considers Psychedelics, New Partnership To Study Psilocybin For Autism, Compass Gets Another Patent
The Week In Psychedelics 
Via Benzinga
Psychedelic Stocks Rebounded 9% Last Week; Small Pharma Was Up 148%
The Psychedelic Compounds-Based Drug Stocks Index was up +8.9% last week albeit still down -18.5% YTD. 
Via Talk Markets
Psychedelics Industry Moving Full-Speed Ahead, When Will Stocks Catch Up?
The psychedelic drug industry is advancing by leaps and bounds, but the stocks have been sliding. Why this disconnect won't last. 
Via Talk Markets
Down 25% in 2021, Is Compass Pathways Undervalued?
It depends on how optimistic you are about its lead program. 
Via The Motley Fool
Phase 2 Trial On Ayahuasca's Active Ingredient Puts Small Pharma On Track To Winning The Psychedelics Race
Small Pharma Inc. (OTCQB:DMTTF) (TSXV: 
Via Benzinga
Psychedelic Unicorn Compass Pathways Receives New Patent Approval
Compass Pathways (NASDAQ:CMPS), a unicorn company in the psychedeli... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation
The Week In Psychedelics 
Via Benzinga
This Company Just Extended its Reach into the United Kingdom by Opening its First Ketamine Therapy Clinic
Photo by cottonbro from Pexels The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner... 
Via Benzinga
Forget The Hype: The Psychedelic Stocks Sector Went Down In The Third Quarter Of 2021
Despite the prevailing hype, the psychedelic sector went down considerably last quarter (July through September) and has gone down even further so far this month. 
Via Talk Markets
There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are
Just two years ago, the psychedelics sector was a small research space reserved for academics and extremely forward-thinking investors. S... 
Via Benzinga
Psychedelic Stocks: Financial Strength, Growth Potential, Compelling Valuations
Blue-chip stocks: grossly inflated valuations and loaded with debt. Psychedelic stocks: lean valuations and loaded with cash. A very attractive option in uncertain markets. 
Via Talk Markets
Why Compass Pathways Stock Dropped 12% in September
Progress continues on the company's work to develop a mental health treatment using a psychoactive drug therapy. 
Via The Motley Fool
1 Recent Healthcare IPO to Put on Your Radar
Here's a pharmaceutical company that could have an incredibly bright future. 
Via The Motley Fool
Topics Initial Public Offering
Exposures Securities Market
Is Ketamine A Psychedelic? Depends On Who You Ask
Ketamine, an FDA-approved anesthetic drug, has recently become the star of the psychedelic medicine movement. As p... 
Via Benzinga
The Three Psychedelics ETFs: Which Is The Best Fit For Your Portfolio?
We compare and contrast the three psychedelic drug ETFs and assess which investor needs each addresses. 
Via Talk Markets
Psyched: First Active Psychedelics ETF Hits NYSE, Compass Dives Into Novel Molecules, Atai Subsidiary Launches Phase 2a Trial
AdvisorShares Launches First NYSE-listed Actively-managed Psychedelics ETF On Thursday, AdvisorShares 
Via Benzinga
Which Psychedelic Stock ETF Is Right For You?
This week the AdvisorShares Psychedelics ETF began trading on the NYSE Arca. Here we compare the make-up of the now 3 psychedelic stock ETFs and two tracking indexes. 
Via Talk Markets
Compass: Psychedelics Unicorn Expands Portfolio Beyond Psilocybin Into Psychedelics 2.0
Psychedelics biotech company Compass Pathways (NASDAQ:CMPS... 
Via Benzinga
Psychedelic Medicine's Top CEOs: Who's Running The Biggest Companies In This Booming Industry?
By Natan Ponieman and Javier Hasse The psychedelic medicine industry is growing by leaps and bounds. Leading this charge is a group of ambitious and visionary corporate... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Cardiff Oncology (NASDAQ: 
Via Benzinga
3 Biotech Stocks Wall Street Expects to Double Soon
All three stocks on this list can more than double your money according to investment bank analysts who cover them. 
Via The Motley Fool
Psychedelic Drug Industry Report Card For 2021
In assessing the psychedelic drug industry, a primary focus for investors is drug development. 
Via Talk Markets
Magic Mushroom Drug Stock Performances YTD
Of the 35 companies involved in clinical stage research of psychedelic substances, 20 are researching the benefits of psilocybin, the primary psychoactive ingredient in “magic mushrooms”. 
Via Talk Markets
Braxia Scientific Launches Broad Criteria Trial On Psilocybin For Depression
Braxia Scientific Corp. (CSE:BRAX) (OTC: 
Via Benzinga
Open-Minded? Buy This Game-Changing Psychedelics Stock Now
Excellent investing opportunities frequently seem outlandish. 
Via The Motley Fool
Topics Supply Chain
Exposures Supply Chain
Psychedelic Drug Patents: All Patents Are Not Created Equal
With many drug patenting opportunities in the emerging psychedelic drug industry, investors need to get up-to-speed on the different types of patents available -- and their strengths and weaknesses. 
Via Talk Markets
Topics Intellectual Property
Exposures Intellectual Property
3 Disruptive Mental Health Stocks to Consider Buying Before They're Huge
They're the first pioneers in exciting new markets. 
Via The Motley Fool
Compass Pathways Q2 Financials: Net Profit Down -38%; Stock Down -59% YTD
COMPASS Pathways plc reported its financial results for the Q2 ending June 30th, 2021, today, and gave an update on recent progress across its business. 
Via Talk Markets
Atai Life Sciences To Research Potent Psychedelic Herb Salvia Divinorum Through Its New Subsidiary
Atai Life Sciences (NASDAQ:ATAI) has announced the launch ... 
Via Benzinga
COMPASS Pathways plc (CMPS) Q2 2021 Earnings Call Transcript
CMPS earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
< Previous 1 2
...
18 19 20 21 22 23 24 25 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.